Fibrosis Progression in African Americans and Caucasian Americans With Chronic Hepatitis C

Clinical Gastroenterology and Hepatology

Volumn 6, Issue 12, 2008, Pages 1403-1411

  Terrault, Norah A ^a   Im, Kelly ^b   Boylan, Ross ^a   Bacchetti, Peter ^a   Kleiner, David E ^c   Fontana, Robert J ^d   Hoofnagle, Jay H ^e   Belle, Steven H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE;

ADULT; AFRICAN AMERICAN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE DURATION; EUROPEAN AMERICAN; FEMALE; GENOTYPE; HAZARD RATIO; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PROBABILITY; RACE; RISK FACTOR; STATISTICAL ANALYSIS; STEATOSIS;

ADULT; AFRICAN AMERICANS; COHORT STUDIES; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MODELS, STATISTICAL; RISK FACTORS; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 57149114712     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2008.08.006     Document Type: Article

References (33)

1. Poynard T., Ratziu V., Charlotte F., et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 34 (2001) 730-739
2. Benhamou Y., Bochet M., Di Martino V., et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients: the Multivirc Group. Hepatology 30 (1999) 1054-1058
3. Monto A., Alonzo J., Watson J., et al. Steatosis in chronic hepatitis C; relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 36 (2002) 729-736
4. Wright M., Goldin R., Fabre A., et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 52 (2003) 574-579
5. Wiley T.E., Brown J., and Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol 97 (2002) 700-706
6. Crosse K., Umeadi O., Anania F., et al. Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clin Gastroenterol Hepatol 2 (2004) 463-468
7. Sterling R., Stravitz R., Luketic V., et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol 2 (2004) 469-473
8. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 (1999) 745-750
9. Davila J., Morgan R., Shaib Y., et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 127 (2004) 1372-1380
10. Conjeevaram H.S., Fried M.W., Jeffers L.J., et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131 (2006) 470-477
11. Hagan H., Thiede H., and Des Jarlais D.C. Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion. Epidemiology 15 (2004) 543-349
12. Garfein R.S., Doherty M.C., Monterroso E.R., et al. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 18 Suppl 1 (1998) S11-S19
13. Thorpe L.E., Ouellet L.J., Levy J.R., et al. Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-1999. J Infect Dis 182 (2000) 1588-1594
14. Poynard T., Bedossa P., and Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C: the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349 (1997) 825-832
15. Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
16. Schafer J.S. Multiple imputation: a primer. Stat Methods Med Res 8 (1999) 3-15
17. Kalbfleisch J., and Lawless J. The analysis of panel data under a Markov assumption. J Am Stat Assoc 80 (1985) 863-871
18. Kay R. A Markov model for analysing cancer markers and disease states in survival studies. Biometrics 42 (1986) 855-865
19. Gentleman R., Lawless J., Lindsey J., et al. Multi-state Markov models for analysing incomplete disease history data with illustrations for HIV disease. Stat Med 13 (1994) 805-821
20. Satten G., and Longini I. Markov chains with measurement error: estimating the 'true' course of a marker of the progression of human immunodeficiency virus disease. Applied Statistics in Medicine 45 (1996) 275-309
21. Jackson C., and Sharples L. Hidden Markov models for the onset and progression of bronchiolitis obliterans syndrome in lung transplant recipients. Stat Med 21 (2002) 113-128
22. Jackson C., Sharples L., Thompson S., et al. Multi-state Markov models for disease progression with classification error. The Statistician 52 (2003) 193-2003
23. Little R.J.A., and Rubin D.B. Statistical analysis with missing data (1987), Wiley, New York
24. Marshall G., and Jones R. Multi-state Markov models and diabetic retinopathy. Stat Med 14 (1995)
25. Bedossa P., Dargere D., and Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38 (2003) 1449-1457
26. Colloredo G., Guido M., Sonzogni A., et al. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 39 (2003) 239-244
27. Fontana R.J., Kleiner D.E., Bilonick R., et al. Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology 44 (2006) 925-935
28. Seeff L., Miller R., Rabkin C., et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 32 (2000) 105-111
29. Vogt M., Lang T., Frosner G., et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 341 (1999) 866-870
30. Levine R.A., Sanderson S.O., Ploutz-Snyder R., et al. Assessment of fibrosis progression in untreated irish women with chronic hepatitis C contracted from immunoglobulin anti-D. Clin Gastroenterol Hepatol 4 (2006) 1271-1277
31. Thomas D.L., Astemborski J., Rai R.M., et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284 (2000) 450-456
32. Brunetti E., Silini E., Pistorio A., et al. Coarse vs. fine needle aspiration biopsy fro the assessment of diffuse liver disease from hepatitis C virus-related chronic hepatitis. J Hepatol 40 (2004) 501-506
33. Freeman A.J., Dore G.J., Law M.G., et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 34 (2001) 809-816